Highlighting 'Pay For Delay' Concerns

Law360, New York (February 3, 2012, 1:28 PM EST) -- The U.S. Federal Trade Commission (FTC) has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand-name pharmaceutical companies are using the threat of launching an authorized generic to make deals that delay generic entry.

These reports shine a spotlight on the interplay between authorized generics and pharmaceutical patent settlements, and indicate strong FTC opposition to a practice that has never been found unlawful.

Report on Authorized Generics

On Aug. 31, 2011, the FTC issued its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.